The DOI matches its Crossref record; 482 of the 482 references it cites were found in a registry or an index.
The multi-factorial nature of clinical multidrug resistance in cancer
Abstract
Curative cancer therapy remains a major challenge particularly in cancers displaying multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a wide array of anticancer drugs harboring distinct structures and mechanisms of action. The multiple factors involved in mediating MDR may include host factors, tumor factors as well as tumor-host interactions. Among the host factors are genetic variants and drug-drug interactions. The plethora of tumor factors involves decreased drug uptake primarily via impaired influx transporters, increased drug efflux predominantly due to the overexpression of MDR efflux transporters of the ATP-binding cassette superfamily or due to drug efflux mediated by extracellular vesicles (EVs) or drug-loaded lysosomes undergoing exocytosis, deregulation of cell death mechanisms (i.e. anti-apoptotic modalities), enhanced DNA damage repair, epigenetic alterations and/or deregulation of microRNAs. The intratumor heterogeneity and dynamics, along with cancer stem cell plasticity, are important tumor factors. Among the tumor-host interactions are the role of the tumor microenvironment, selective pressure of various stressor conditions and agents, acidic pH and the intracellular transfer of traits mediated by EVs. The involvement of these diverse factors in MDR, highlights the need for precision medicine and real-time personalized treatments of individual cancer patients. In this review, written by a group of researchers from COST Action STRATAGEM "New diagnostic and therapeutic tools against multidrug resistant tumors", we aim to bring together these multidisciplinary and interdisciplinary features of MDR cancers. Importantly, it is becoming increasingly clear that deciphering the molecular mechanisms underlying anticancer drug resistance, will pave the way towards the development of novel precision medicine treatment modalities that are able to surmount distinct and well-defined mechanisms of anticancer drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Wu, Y., Jin, D., Wang, X., Du, J., Di, W., An, J., Shao, C., & Guo, J. (2019) · Journal of Oncology · doi:10.1155/2019/8607859 · Cited by 39
RetractedZhu, X., Zhao, H., Lin, Z., & Zhang, G. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.50 · Cited by 30
RetractedZhao, L., Shan, Y., Liu, B., Li, Y., & Li, J. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.223 · Cited by 23
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Communication by Extracellular Vesicles: Where We Are and Where We Need to Go
Tkach, M., & Théry, C. (2016) · Cell · doi:10.1016/j.cell.2016.01.043 · Cited by 3,444
Modeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
Murray, D. D., Suzuki, K., Law, M., Trebicka, J., Neuhaus, J., Wentworth, D., Johnson, M., Vjecha, M. J., Kelleher, A. D., Emery, S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139981 · Cited by 2,740
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Puram, S. V., Tirosh, I., Parikh, A. S., Patel, A. P., Yizhak, K., Gillespie, S., Rodman, C., Luo, C. L., Mroz, E. A., Emerick, K. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.044 · Cited by 2,557
A Gene Network Regulating Lysosomal Biogenesis and Function
Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., Gennarino, V. A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R. S., et al. (2009) · Science · doi:10.1126/science.1174447 · Cited by 2,543
The role of MicroRNAs in human cancer
Peng, Y., & Croce, C. M. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2015.4 · Cited by 2,483
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476
Epigenetics: A landscape takes shape
Goldberg, A. D., Allis, C. D., & Bernstein, E. (2007) · Cell · doi:10.1016/j.cell.2007.02.006 · Cited by 2,466
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Gasque, G., Conway, S., Huang, J., Rao, Y., & Vosshall, L. B. (2013) · Scientific Reports · doi:10.1038/srep02120 · Cited by 2,292
Regulation of microRNA function in animals
Gebert, L. F. R., & MacRae, I. J. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0045-7 · Cited by 2,284
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Dysregulated pH: a perfect storm for cancer progression
Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3110 · Cited by 2,237
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“Some of these lipophilic cytotoxic agents diffuse passively across lipid bilayers most efficiently in their uncharged form (Trédan et al., 2007).”
BackgroundClonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
Pharmacogenomics Knowledge for Personalized Medicine
Whirl-Carrillo, M., McDonagh, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F., Altman, R. B., & Klein, T. E. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.96 · Cited by 1,796
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569
Interfering with pH regulation in tumours as a therapeutic strategy
Neri, D., & Supuran, C. T. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3554 · Cited by 1,547
Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Identification of the tumour transition states occurring during EMT
Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Van Keymeulen, A., Brown, D., Moers, V., Lemaire, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0040-3 · Cited by 1,495
Extracellular vesicles in cancer — implications for future improvements in cancer care
Xu, R., Rai, A., Chen, M., Suwakulsiri, W., Greening, D. W., & Simpson, R. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0036-9 · Cited by 1,445
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
Role of Glutathione in Cancer Progression and Chemoresistance
Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/972913 · Cited by 1,208
Anoikis molecular pathways and its role in cancer progression
Paoli, P., Giannoni, E., & Chiarugi, P. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.06.026 · Cited by 1,160
Hotchkiss, R. S., Strasser, A., McDunn, J. E., & Swanson, P. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0901217 · Cited by 1,154
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
Kim, C., Gao, R., Sei, E., Brandt, R., Hartman, J., Hatschek, T., Crosetto, N., Foukakis, T., & Navin, N. E. (2018) · Cell · doi:10.1016/j.cell.2018.03.041 · Cited by 1,104
Green, D. R., & Llambi, F. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006080 · Cited by 1,101
Molecular targeted therapy: Treating cancer with specificity
Lee, Y. T., Tan, Y. J., & Oon, C. E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.034 · Cited by 1,067
Regulation of Homologous Recombination in Eukaryotes
Heyer, W.-D., Ehmsen, K. T., & Liu, J. (2010) · Annual Review of Genetics · doi:10.1146/annurev-genet-051710-150955 · Cited by 1,066
The Biology of Cancer Stem Cells
Lobo, N. A., Shimono, Y., Qian, D., & Clarke, M. F. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010305.104154 · Cited by 1,043
Whole-genome analysis informs breast cancer response to aromatase inhibition
Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., Van Tine, B. A., Hoog, J., Goiffon, R. J., Goldstein, T. C., et al. (2012) · Nature · doi:10.1038/nature11143 · Cited by 1,023
Krebs, A. M., Mitschke, J., Lasierra Losada, M., Schmalhofer, O., Boerries, M., Busch, H., Boettcher, M., Mougiakakos, D., Reichardt, W., Bronsert, P., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3513 · Cited by 975
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science · doi:10.1126/science.1256930 · Cited by 965
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Neoantigen-directed immune escape in lung cancer evolution
The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1032-7 · Cited by 946
Modelling cancer in microfluidic human organs-on-chips
Sontheimer-Phelps, A., Hassell, B. A., & Ingber, D. E. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0104-6 · Cited by 906
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 864
Zhou, S.-L., Zhou, Z.-J., Hu, Z.-Q., Huang, X.-W., Wang, Z., Chen, E.-B., Fan, J., Cao, Y., Dai, Z., & Zhou, J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.040 · Cited by 852
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice
Bhatia, M., Wang, J. C. Y., Kapp, U., Bonnet, D., & Dick, J. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5320 · Cited by 850
(2002) · PubMed · Cited by 840
The role of cellular reactive oxygen species in cancer chemotherapy
Yang, H., Villani, R. M., Wang, H., Simpson, M. J., Roberts, M. S., Tang, M., & Liang, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0909-x · Cited by 794
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Aktas, B., Tewes, M., Fehm, T., Hauch, S., Kimmig, R., & Kasimir-Bauer, S. (2009) · Breast Cancer Research · doi:10.1186/bcr2333 · Cited by 736
Anoikis: an emerging hallmark in health and diseases
Taddei, M., Giannoni, E., Fiaschi, T., & Chiarugi, P. (2012) · The Journal of Pathology · doi:10.1002/path.3000 · Cited by 716
Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular Clearance
Medina, D. L., Fraldi, A., Bouche, V., Annunziata, F., Mansueto, G., Spampanato, C., Puri, C., Pignata, A., Martina, J. A., Sardiello, M., et al. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.07.016 · Cited by 716
Cancer stem cell definitions and terminology: the devil is in the details
Valent, P., Bonnet, D., De Maria, R., Lapidot, T., Copland, M., Melo, J. V., Chomienne, C., Ishikawa, F., Schuringa, J. J., Stassi, G., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3368 · Cited by 692
Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Self-citationResistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α
Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R. D., Engh, J., Iwama, T., Kunisada, T., Kassam, A. B., et al. (2009) · Oncogene · doi:10.1038/onc.2009.252 · Cited by 656
Resolving genetic heterogeneity in cancer
Turajlic, S., Sottoriva, A., Graham, T., & Swanton, C. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0114-6 · Cited by 653
The molecular mechanisms of chemoresistance in cancers
Zheng, H.-C. (2017) · Oncotarget · doi:10.18632/oncotarget.19048 · Cited by 624
Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry
Berdasco, M., & Esteller, M. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.10.005 · Cited by 618
Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy
Izumi, H., Torigoe, T., Ishiguchi, H., Uramoto, H., Yoshida, Y., Tanabe, M., Ise, T., Murakami, T., Yoshida, T., Nomoto, M., et al. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00106-3 · Cited by 613
Burstein, H. J., Krilov, L., Aragon-Ching, J. B., Baxter, N. N., Chiorean, E. G., Chow, W. A., De Groot, J. F., Devine, S. M., DuBois, S. G., El-Deiry, W. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5292 · Cited by 601
Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance
Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.011 · Cited by 598
Maacha, S., Bhat, A. A., Jimenez, L., Raza, A., Haris, M., Uddin, S., & Grivel, J.-C. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0965-7 · Cited by 572
Tung, N., Lin, N. U., Kidd, J., Allen, B. A., Singh, N., Wenstrup, R. J., Hartman, A.-R., Winer, E. P., & Garber, J. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0747 · Cited by 556
Baretti, M., & Le, D. T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.004 · Cited by 556
Targeting BCL-2 regulated apoptosis in cancer
Campbell, K. J., & Tait, S. W. G. (2018) · Open Biology · doi:10.1098/rsob.180002 · Cited by 545
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
Recent advances in apoptosis, mitochondria and drug resistance in cancer cells
Indran, I. R., Tufo, G., Pervaiz, S., & Brenner, C. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.03.010 · Cited by 526
Potential role of HER2‐overexpressing exosomes in countering trastuzumab‐based therapy
Ciravolo, V., Huber, V., Ghedini, G. C., Venturelli, E., Bianchi, F., Campiglio, M., Morelli, D., Villa, A., Mina, P. D., Menard, S., et al. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22773 · Cited by 514
Su, K.-Y., Chen, H.-Y., Li, K.-C., Kuo, M.-L., Yang, J. C.-H., Chan, W.-K., Ho, B.-C., Chang, G.-C., Shih, J.-Y., Yu, S.-L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3224 · Cited by 499
FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension
Kaminskas, E., Farrell, A. T., Wang, Y.-C., Sridhara, R., & Pazdur, R. (2005) · The Oncologist · doi:10.1634/theoncologist.10-3-176 · Cited by 490
Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery
Weeber, F., Ooft, S. N., Dijkstra, K. K., & Voest, E. E. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.012 · Cited by 486
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Palmeira, A., Sousa, E., H. Vasconcelos, M., & M. Pinto, M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800167392 · Cited by 484
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
Self-citationFactors determining DNA double‐strand break repair pathway choice in G2 phase
Shibata, A., Conrad, S., Birraux, J., Geuting, V., Barton, O., Ismail, A., Kakarougkas, A., Meek, K., Taucher‐Scholz, G., Löbrich, M., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.27 · Cited by 479
Spatial genomic heterogeneity within localized, multifocal prostate cancer
Boutros, P. C., Fraser, M., Harding, N. J., de Borja, R., Trudel, D., Lalonde, E., Meng, A., Hennings-Yeomans, P. H., McPherson, A., Sabelnykova, V. Y., et al. (2015) · Nature Genetics · doi:10.1038/ng.3315 · Cited by 477
Kelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., & Paszat, L. F. (2010) · BMJ · doi:10.1136/bmj.c693 · Cited by 466
Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
Gonen, N., & Assaraf, Y. G. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.07.002 · Cited by 437
Self-citationMacrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer
Halbrook, C. J., Pontious, C., Kovalenko, I., Lapienyte, L., Dreyer, S., Lee, H.-J., Thurston, G., Zhang, Y., Lazarus, J., Sajjakulnukit, P., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.001 · Cited by 419
Kondrashova, O., Nguyen, M., Shield-Artin, K., Tinker, A. V., Teng, N. N. H., Harrell, M. I., Kuiper, M. J., Ho, G.-Y., Barker, H., Jasin, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0419 · Cited by 407
Systems analysis of intracellular pH vulnerabilities for cancer therapy
Persi, E., Duran-Frigola, M., Damaghi, M., Roush, W. R., Aloy, P., Cleveland, J. L., Gillies, R. J., & Ruppin, E. (2018) · Nature Communications · doi:10.1038/s41467-018-05261-x · Cited by 406
Role of the breast cancer resistance protein (ABCG2) in drug transport
Mao, Q. (2005) · The AAPS Journal · doi:10.1208/aapsj070112 · Cited by 405
Haslehurst, A. M., Koti, M., Dharsee, M., Nuin, P., Evans, K., Geraci, J., Childs, T., Chen, J., Li, J., Weberpals, J., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-91 · Cited by 402
Buys, S. S., Sandbach, J. F., Gammon, A., Patel, G., Kidd, J., Brown, K. L., Sharma, L., Saam, J., Lancaster, J., & Daly, M. B. (2017) · Cancer · doi:10.1002/cncr.30498 · Cited by 399
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
Senthebane, D. A., Rowe, A., Thomford, N. E., Shipanga, H., Munro, D., Mazeedi, M. A. M. A., Almazyadi, H. A. M., Kallmeyer, K., Dandara, C., Pepper, M. S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071586 · Cited by 399
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390 · cited 1×
“The number of demethylated genes from tumor biopsies was greater in patients with a PFS longer than 6 months than in those with less than 6 months PFS, and methylation of four genes correlated with survival (Matei et al., 2012).”
BackgroundA systematic review of geographical variation in access to chemotherapy
Chamberlain, C., Owen-Smith, A., Donovan, J., & Hollingworth, W. (2016) · BMC Cancer · doi:10.1186/s12885-015-2026-y · Cited by 390
Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient
Mayer, L. D., Bally, M. B., & Cullis, P. R. (1986) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(86)90105-7 · Cited by 379
Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer
Brooks, M. D., Burness, M. L., & Wicha, M. S. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.08.014 · Cited by 374
Aung, T., Chapuy, B., Vogel, D., Wenzel, D., Oppermann, M., Lahmann, M., Weinhage, T., Menck, K., Hupfeld, T., Koch, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102855108 · Cited by 374
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Curtin, N. J., & Szabo, C. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.006 · Cited by 369
Lecharpentier, A., Vielh, P., Perez-Moreno, P., Planchard, D., Soria, J. C., & Farace, F. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.405 · Cited by 367
Drug interactions in cancer therapy
Scripture, C. D., & Figg, W. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1887 · Cited by 366
Cell membrane modulation as adjuvant in cancer therapy
Zalba, S., & ten Hagen, T. L. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.008 · Cited by 365
Epigenetic Therapeutics: A New Weapon in the War Against Cancer
Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 363
Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics
Gerweck, L. E., Vijayappa, S., & Kozin, S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0024 · Cited by 362
Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors
Saghafinia, S., Mina, M., Riggi, N., Hanahan, D., & Ciriello, G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.082 · Cited by 357
The p KaDistribution of Drugs: Application to Drug Discovery
Manallack, D. T. (2007) · Perspectives in Medicinal Chemistry · doi:10.1177/1177391x0700100003 · Cited by 354
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 352
Overview: ABC Transporters and Human Disease
Gottesman, M. M., & Ambudkar, S. V. (2001) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1012866803188 · Cited by 350
Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
Gotink, K. J., Broxterman, H. J., Labots, M., de Haas, R. R., Dekker, H., Honeywell, R. J., Rudek, M. A., Beerepoot, L. V., Musters, R. J., Jansen, G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1667 · Cited by 345
Self-citationMolecular basis of antifolate resistance
Assaraf, Y. G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9049-z · Cited by 338
Self-citationBudha, N. R., Frymoyer, A., Smelick, G. S., Jin, J. Y., Yago, M. R., Dresser, M. J., Holden, S. N., Benet, L. Z., & Ware, J. A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.73 · Cited by 338
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Barber, L. J., Sandhu, S., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D. N., Reis-Filho, J. S., Moreno, V., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4140 · Cited by 336
Goetz, M. P., Sangkuhl, K., Guchelaar, H., Schwab, M., Province, M., Whirl‐Carrillo, M., Symmans, W. F., McLeod, H. L., Ratain, M. J., Zembutsu, H., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1007 · Cited by 336
Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients
Riechelmann, R. P., Tannock, I. F., Wang, L., Saad, E. D., Taback, N. A., & Krzyzanowska, M. K. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk130 · Cited by 328
Song, H., Dicks, E., Ramus, S. J., Tyrer, J. P., Intermaggio, M. P., Hayward, J., Edlund, C. K., Conti, D., Harrington, P., Fraser, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2408 · Cited by 328
Toward a Better Understanding of the Complexity of Cancer Drug Resistance
Gottesman, M. M., Lavi, O., Hall, M. D., & Gillet, J.-P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103111 · Cited by 327
Feng, Y.-X., Sokol, E. S., Del Vecchio, C. A., Sanduja, S., Claessen, J. H. L., Proia, T. A., Jin, D. X., Reinhardt, F., Ploegh, H. L., Wang, Q., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0945 · Cited by 319
Epigenetic therapy for ovarian cancer: promise and progress
Moufarrij, S., Dandapani, M., Arthofer, E., Gomez, S., Srivastava, A., Lopez-Acevedo, M., Villagra, A., & Chiappinelli, K. B. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0602-0 · Cited by 319
Selvakumaran, M., Pisarcik, D., Bao, R., Yeung, A. T., & Hamilton, T. C. (2003) · PubMed · Cited by 317
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Self-citationYang, Z., Qi, Y., Lai, N., Zhang, J., Chen, Z., Liu, M., Zhang, W., Luo, R., & Kang, S. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0664-4 · Cited by 305
Xu, J., Yang, P., Xue, S., Sharma, B., Sanchez-Martin, M., Wang, F., Beaty, K. A., Dehan, E., & Parikh, B. (2019) · Human Genetics · doi:10.1007/s00439-019-01970-5 · Cited by 305
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Wilting, R. H., & Dannenberg, J.-H. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.008 · Cited by 303
Multidrug resistance associated proteins in multidrug resistance
Sodani, K., Patel, A., Kathawala, R. J., & Chen, Z.-S. (2012) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10329 · Cited by 300
The epithelial-mesenchymal tansition (EMT) and colorectal cancer progression
Bates, R. C., & Mercurio, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.4.1655 · Cited by 298
Yin, Y., Yao, S., Hu, Y., Feng, Y., Li, M., Bian, Z., Zhang, J., Qin, Y., Qi, X., Zhou, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1283 · Cited by 296
Bellon, S. F., Coleman, J. H., & Lippard, S. J. (1991) · Biochemistry · doi:10.1021/bi00246a021 · Cited by 291
Peetla, C., Vijayaraghavalu, S., & Labhasetwar, V. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.004 · Cited by 289
Lysosomal Sequestration of Amine-Containing Drugs: Analysis and Therapeutic Implications
Kaufmann, A. M., & Krise, J. P. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20792 · Cited by 284
Issa, J.-P. J., Roboz, G., Rizzieri, D., Jabbour, E., Stock, W., O'Connell, C., Yee, K., Tibes, R., Griffiths, E. A., Walsh, K., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00038-8 · Cited by 283
Classification of Circulating Tumor Cells by Epithelial-Mesenchymal Transition Markers
Wu, S., Liu, S., Liu, Z., Huang, J., Pu, X., Li, J., Yang, D., Deng, H., Yang, N., & Xu, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123976 · Cited by 282
Causes, consequences, and therapy of tumors acidosis
Pillai, S. R., Damaghi, M., Marunaka, Y., Spugnini, E. P., Fais, S., & Gillies, R. J. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09792-7 · Cited by 282
Oza, A. M., Tinker, A. V., Oaknin, A., Shapira-Frommer, R., McNeish, I. A., Swisher, E. M., Ray-Coquard, I., Bell-McGuinn, K., Coleman, R. L., O'Malley, D. M., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.08.022 · Cited by 281
Cancer stem cells: A review from origin to therapeutic implications
Atashzar, M. R., Baharlou, R., Karami, J., Abdollahi, H., Rezaei, R., Pourramezan, F., & Zoljalali Moghaddam, S. H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29044 · Cited by 281
Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
van Leeuwen, R. W. F., van Gelder, T., Mathijssen, R. H. J., & Jansman, F. G. A. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70579-5 · Cited by 279
Hyun, K.-A., Koo, G.-B., Han, H., Sohn, J., Choi, W., Kim, S.-I., Jung, H.-I., & Kim, Y.-S. (2016) · Oncotarget · doi:10.18632/oncotarget.8250 · Cited by 274
Extracellular vesicles and anti-cancer drug resistance
Namee, N. M., & O'Driscoll, L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.003 · Cited by 274
Histone Acetylation Regulates Intracellular pH
McBrian, M. A., Behbahan, I. S., Ferrari, R., Su, T., Huang, T.-W., Li, K., Hong, C. S., Christofk, H. R., Vogelauer, M., Seligson, D. B., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.025 · Cited by 272
Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
van Leeuwen, R. W. F., Brundel, D. H. S., Neef, C., van Gelder, T., Mathijssen, R. H. J., Burger, D. M., & Jansman, F. G. A. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.48 · Cited by 264
Deciphering the cells of origin of squamous cell carcinomas
Sánchez-Danés, A., & Blanpain, C. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0024-5 · Cited by 261
Taylor, S., Spugnini, E. P., Assaraf, Y. G., Azzarito, T., Rauch, C., & Fais, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.004 · Cited by 259
Self-citationKazmi, F., Hensley, T., Pope, C., Funk, R. S., Loewen, G. J., Buckley, D. B., & Parkinson, A. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050054 · Cited by 259
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen, R. H. J., Marsh, S., Karlsson, M. O., Xie, R., Baker, S. D., Verweij, J., Sparreboom, A., & McLeod, H. L. (2003) · PubMed · Cited by 258
Cell-of-Origin of Cancer versus Cancer Stem Cells: Assays and Interpretations
Rycaj, K., & Tang, D. G. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0798 · Cited by 256
Sullivan, R., Paré, G. C., Frederiksen, L. J., Semenza, G. L., & Graham, C. H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0198 · Cited by 243
Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression
Satelli, A., Mitra, A., Brownlee, Z., Xia, X., Bellister, S., Overman, M. J., Kopetz, S., Ellis, L. M., Meng, Q. H., & Li, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0894 · Cited by 242
Meidhof, S., Brabletz, S., Lehmann, W., Preca, B., Mock, K., Ruh, M., Schüler, J., Berthold, M., Weber, A., Burk, U., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404396 · Cited by 229
Zhitomirsky, B., & Assaraf, Y. G. (2015) · Oncotarget · doi:10.18632/oncotarget.2732 · Cited by 225
Self-citationGenomic Instability and Cancer
Wei Dai, Y. Y. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000165 · Cited by 225
Zhu, Y., Yu, F., Jiao, Y., Feng, J., Tang, W., Yao, H., Gong, C., Chen, J., Su, F., Zhang, Y., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0071 · Cited by 221
The Warburg metabolism fuels tumor metastasis
Lu, J. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09794-5 · Cited by 218
Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes
Yardley, D. A. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/137414 · Cited by 216
McLeod, H. L., Sargent, D. J., Marsh, S., Green, E. M., King, C. R., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Thibodeau, S. N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.7943 · Cited by 216
Molecular mechanism and regulation of autophagy1
YANG, Y.-P., LIANG, Z.-Q., GU, Z.-L., & QIN, Z.-H. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00235.x · Cited by 214
Intratumoral Heterogeneity of the Epigenome
Mazor, T., Pankov, A., Song, J. S., & Costello, J. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.009 · Cited by 214
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
Wind, S., Schmid, U., Freiwald, M., Marzin, K., Lotz, R., Ebner, T., Stopfer, P., & Dallinger, C. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00766-0 · Cited by 212
Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
K. Tiwari, A., Sodani, K., Dai, C.-L., R. Ashby, C., & Chen, Z.-S. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795164048 · Cited by 211
Fang, L., Li, H., Wang, L., Hu, J., Jin, T., Wang, J., & Yang, B. B. (2014) · Oncotarget · doi:10.18632/oncotarget.1614 · Cited by 209
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Yap, T. A., Sandhu, S. K., Carden, C. P., & de Bono, J. S. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20095 · Cited by 208
Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Wilson, T., Johnston, P., & Longley, D. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166547 · Cited by 203
Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy
Lee, J.-K., Liu, Z., Sa, J. K., Shin, S., Wang, J., Bordyuh, M., Cho, H. J., Elliott, O., Chu, T., Choi, S. W., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0209-6 · Cited by 203
Saladores, P., Mürdter, T., Eccles, D., Chowbay, B., Zgheib, N. K., Winter, S., Ganchev, B., Eccles, B., Gerty, S., Tfayli, A., et al. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.34 · Cited by 199
Regulation of multidrug resistance by microRNAs in anti-cancer therapy
An, X., Sarmiento, C., Tan, T., & Zhu, H. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.09.002 · Cited by 194
Li, J., Cusatis, G., Brahmer, J., Sparreboom, A., Robey, R. W., Bates, S. E., Hidalgo, M., & Baker, S. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.3.3763 · Cited by 191
Mechanism and regulation of incisions during DNA interstrand cross-link repair
Zhang, J., & Walter, J. C. (2014) · DNA Repair · doi:10.1016/j.dnarep.2014.03.018 · Cited by 190
Smelick, G. S., Heffron, T. P., Chu, L., Dean, B., West, D. A., DuVall, S. L., Lum, B. L., Budha, N., Holden, S. N., Benet, L. Z., et al. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400403s · Cited by 190
Structure and mechanism of ABC transporters
Locher, K. P. (2004) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2004.06.005 · Cited by 189
Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment
Cordani, M., & Somoza, Á. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2973-y · Cited by 188
DNA damage response – A double-edged sword in cancer prevention and cancer therapy
Tian, H., Gao, Z., Li, H., Zhang, B., Wang, G., Zhang, Q., Pei, D., & Zheng, J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.12.038 · Cited by 186
Proton channels and exchangers in cancer
Spugnini, E. P., Sonveaux, P., Stock, C., Perez-Sayans, M., De Milito, A., Avnet, S., Garcìa, A. G., Harguindey, S., & Fais, S. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.10.015 · Cited by 186
Kim, D. H. (., Sriharsha, L., Xu, W., Kamel-Reid, S., Liu, X., Siminovitch, K., Messner, H. A., & Lipton, J. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0145 · Cited by 186
Molecular characterization of breast cancer CTCs associated with brain metastasis
Boral, D., Vishnoi, M., Liu, H. N., Yin, W., Sprouse, M. L., Scamardo, A., Hong, D. S., Tan, T. Z., Thiery, J. P., Chang, J. C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00196-1 · Cited by 186
Conlon, G. A., & Murray, G. I. (2019) · The Journal of Pathology · doi:10.1002/path.5225 · Cited by 185
Determining the optimal dose in the development of anticancer agents
Mathijssen, R. H. J., Sparreboom, A., & Verweij, J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.40 · Cited by 184
Ma, X., Chen, Z., Hua, D., He, D., Wang, L., Zhang, P., Wang, J., Cai, Y., Gao, C., Zhang, X., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400272111 · Cited by 180
Ma, X., Cai, Y., He, D., Zou, C., Zhang, P., Lo, C. Y., Xu, Z., Chan, F. L., Yu, S., Chen, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202989109 · Cited by 179
Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma
Lan, F., Qing, Q., Pan, Q., Hu, M., Yu, H., & Yue, X. (2018) · Cellular Oncology · doi:10.1007/s13402-017-0355-3 · Cited by 179
Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
Van Roosbroeck, K., Fanini, F., Setoyama, T., Ivan, C., Rodriguez-Aguayo, C., Fuentes-Mattei, E., Xiao, L., Vannini, I., Redis, R. S., D'Abundo, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1025 · Cited by 178
Cited by
Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Self-citationAnticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Self-citationApoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 371
Metadata
- Authors
- Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 46
- Pages
- 100645
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2974459221
- Cited by
- 528
- References
- 482
- FWCI
- 21.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.